Cytosorbents Corporation
CTSO
$0.59
$0.000.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 9.23M | 9.49M | 9.62M | 8.73M | 9.15M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.23M | 9.49M | 9.62M | 8.73M | 9.15M |
| Cost of Revenue | 2.43M | 2.82M | 2.80M | 2.52M | 2.90M |
| Gross Profit | 6.80M | 6.67M | 6.81M | 6.21M | 6.26M |
| SG&A Expenses | 9.61M | 8.41M | 9.17M | 8.43M | 7.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.29M | 12.15M | 13.23M | 12.61M | 12.86M |
| Operating Income | -4.05M | -2.66M | -3.62M | -3.89M | -3.71M |
| Income Before Tax | -5.50M | -3.57M | 1.95M | -1.48M | -9.26M |
| Income Tax Expenses | 0.00 | -401.00K | -- | -- | -1.69M |
| Earnings from Continuing Operations | -5.50M | -3.17M | 1.95M | -1.48M | -7.57M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.50M | -3.17M | 1.95M | -1.48M | -7.57M |
| EBIT | -4.05M | -2.66M | -3.62M | -3.89M | -3.71M |
| EBITDA | -3.69M | -2.30M | -3.21M | -3.52M | -3.32M |
| EPS Basic | -0.09 | -0.05 | 0.03 | -0.02 | -0.14 |
| Normalized Basic EPS | -0.05 | -0.03 | 0.02 | -0.02 | -0.11 |
| EPS Diluted | -0.09 | -0.05 | 0.03 | -0.02 | -0.14 |
| Normalized Diluted EPS | -0.05 | -0.03 | 0.02 | -0.02 | -0.11 |
| Average Basic Shares Outstanding | 62.80M | 62.75M | 62.61M | 60.73M | 54.71M |
| Average Diluted Shares Outstanding | 62.80M | 62.75M | 67.17M | 60.73M | 54.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |